Core Viewpoint - A securities class action lawsuit has been filed against PACS Group, Inc. for allegedly making materially false and misleading statements regarding its business operations and financial performance during the Class Period from April 11, 2024, to November 5, 2024 [1][2]. Group 1: Allegations Against PACS Group - The lawsuit claims that PACS engaged in a scheme to submit false Medicare claims, which accounted for over 100% of its operating and net income from 2020 to 2023 [2]. - It is alleged that PACS billed Medicare for thousands of unnecessary respiratory and sensory integration therapies [2]. - The company is accused of falsifying documentation related to licensure and staffing, leading to misleading statements about its business prospects [2]. Group 2: Legal Process and Participation - Investors in PACS have until January 13, 2025, to seek appointment as lead plaintiff, representing the class in the litigation [3]. - A lead plaintiff is typically the investor or group of investors with the largest financial interest in the case and is responsible for directing the litigation [3]. - Participation as a lead plaintiff does not affect an investor's ability to share in any recovery from the lawsuit [3]. Group 3: Law Firm Information - Kessler Topaz Meltzer & Check, LLP is the law firm handling the class action and has a reputation for prosecuting class actions globally, recovering billions for victims of corporate misconduct [4]. - The firm encourages PACS investors who have suffered losses to contact them for more information [4].
PACS Deadline in 6 Days: Kessler Topaz Meltzer & Check, LLP Reminds PACS Group, Inc. (PACS) Investors of Filing Deadline in Class Action Lawsuit